A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients
Cancers · 29.04.2026 · 18 (9) · 1423
DOI: 10.3390/cancers18091423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.04.2026. Verfasst von Shimaa Sherif und 24 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Sidra Medicine, Doha 26999, Qatar. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund, Italian Ministry of Health.
Abstract (Originalsprache)
The immunological composition of the microenvironment has shown relevance for diagnosis, prognosis, and therapy in solid tumors but remains underexplored in acute leukemias. We investigated the significance of the acute myeloid leukemia (AML) bone marrow microenvironment in predicting chemosensitivity and long-term remission in pediatric patients. We analyzed 32 non-promyelocytic pediatric AML patients at diagnosis using a NanoString PanCancer IO 360 assay, RNA sequencing, and deep-phenotype flow cytometry analyses. The findings were validated using the pediatric TARGET AML dataset. A short signature of three interferon (IFN)-related genes (GBP1, PARP12, and TRAT1) distinguished patients with chemosensitive disease and reduced minimal residual disease after induction chemotherapy. The signature stratified patients overall, and within the clinically defined “standard-risk” group, patients with high gene expression at diagnosis had significantly longer overall survival. The leukemia microenvironment associated with this signature showed enrichment of non-exhausted CD4+ and CD8+ T cytotoxic lymphocytes and expansion of CD8+ T effector memory cells re-expressing CD45RA (TEMRA) in patients with a favorable prognosis. Our results show the importance of the bone marrow microenvironment in pediatric AML and provide tools for a refined stratification of “standard-risk” patients, lacking adequate risk-oriented therapies. They also offer a promising guide for tackling immune pathways and exploiting immune-targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Department, Sidra Medicine, Doha 26999, Qatar.
- Pediatric Oncology and Hematology Department and Cell Factory, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy.
- Department of Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
- Department of Oncology, Aga Khan University, Karachi 74800, Pakistan.
- Pathology Department, Sidra Medicine, Doha 26999, Qatar.
- Weill Cornell Medicine-Qatar, Medical Education Division, Doha 24144, Qatar.
ORCID-Profile: Shimaa Sherif, Khadega Ibrahim, Mohammed Toufiq, Fazulur R Vempalli, Kulsoom Ghias, Sandra Sapia, Mohammed Y S Anas, Giusy Gentilcore, Chiara Cugno, Sara Deola
Förderung
- Qatar National Research Fund
- Italian Ministry of Health
Zitieren
APA
Sherif, S., Ali, A., Ibrahim, K., Rinchai, D., Elanbari, M., Kizhakayil, D., Toufiq, M., Vempalli, F. R., Mina, T., Comoli, P., Ghias, K., Fadoo, Z., Herrera, S., Lachica, C. A., Dawoud, E. D. K., Bibawi, H., Sapia, S., Dason, B., Ejaz, A., …, & Deola, S. (2026). A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. Cancers, 18(9), 1423. https://doi.org/10.3390/cancers18091423
Vancouver
Sherif S, Ali A, Ibrahim K, Rinchai D, Elanbari M, Kizhakayil D, et al. A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. Cancers. 2026;18(9):1423. doi:10.3390/cancers18091423
BibTeX
@article{Sherif2026,
author = {Sherif, Shimaa and Ali, Aesha and Ibrahim, Khadega and Rinchai, Darawan and Elanbari, Mohammed and Kizhakayil, Dhanya and Toufiq, Mohammed and Vempalli, Fazulur R and Mina, Tommaso and Comoli, Patrizia and Ghias, Kulsoom and Fadoo, Zehra and Herrera, Sheanna and Lachica, Che-Ann and Dawoud, Enas D K and Bibawi, Hani and Sapia, Sandra and Dason, Blessing and Ejaz, Anila and Anas, Mohammed Y S and Saleh, Ayman and Gentilcore, Giusy and Bedognetti, Davide and Cugno, Chiara and Deola, Sara},
title = {A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1423},
doi = {10.3390/cancers18091423}
}
EUVIMED